Comparison of the acute effects of formoterol (F) and formoterol/budesonide combination (FBC) on blood-gas tensions in patients with acute exacerbation of COPD (AECOPD) Source: Annual Congress 2003 - Progress on therapy for chronic obstructive pulmonary disease Year: 2003
Use of intravenous (IV) aminophylline in acute exacerbations of COPD with decompensated acidotic type 2 respiratory failure (T2RF) requiring non-invasive ventilation (NIV) Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Effect of umeclidinium/vilanterol (UMEC/VI) on inspiratory capacity/total lung capacity ratio in hyperinflated COPD patients Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Effect of pulmonary rehabilitation (PR) on exertional dyspnea and dynamic hyperinflation during six minute walk test in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 209s Year: 2004
Acute effects of higher than customary doses of salmeterol (SM) and salbutamol (SB) in patients with acute exacerbation of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001
Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
Changes of respiratory mechanics (RM) during exacerbations of chronic obstructive pulmonary disease (COPD) requiring noninvasive ventilation (NIV) Source: Annual Congress 2010 - News from noninvasive ventilation Year: 2010
Effect of inhaled vilanterol trifenatate/fluticasone furoate on breathing pattern, dyspnea and respiratory muscle function in severe COPD Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014
Effect of the once-daily long-acting bronchodilator combination umeclidinium/vilanterol (UMEC/VI) and bronchodilator monotherapy on dyspnoea as measured by the transitional dyspnoea index (TDI) in COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014
Effect of short-acting bronchodilators (BDs) on the severity of respiratory muscle (RM) strength in COPD patients (pts) Source: Annual Congress 2013 –COPD treatment Year: 2013
Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD Source: Eur Respir J 2001; 17: 1132-1137 Year: 2001
Effects of aclidinium bromide on exercise endurance, dynamic hyperinflation, physical activity and exertional dyspnoea in patients with moderate to severe COPD Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013
The estimation of respiratory muscles (RM) status by echodensitometry in male patients with acute exacerbation of COPD (AECOPD) Source: Annual Congress 2010 - Interaction between respiratory and peripheral muscles Year: 2010
Effects of arm training on exertional dyspnoea in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 66s Year: 2002
Effects of acute dual bronchodilator treatment (tiotropium + olodaterol) on cardiopulmonary interactions in hyperinflated patients with COPD Source: International Congress 2018 – Advances in exercise physiopathology Year: 2018
Mechanism of improvement of exertional dyspnea during six minute walking test (6MWT) after pulmonary rehabilitation (PR) in COPD Source: Eur Respir J 2005; 26: Suppl. 49, 719s Year: 2005
Effects of tiotropium and salmeterol/fluticasone combination on lung hyperinflation, dyspnea and exercise tolerance in COPD Source: Eur Respir J 2006; 28: Suppl. 50, 33s Year: 2006
TIOSPIR®: Large scale trial of tiotropium Respimat® vs HandiHaler® (HH) in patients (pts) with COPD Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
First dose response to tiotropium in COPD: Impact on dyspnea, lung hyperinflation and distal airways Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
The effects of adding formoterol (F) and tiotropium (T) on exercise performance and breathlessness in patients with COPD Source: Eur Respir J 2005; 26: Suppl. 49, 577s Year: 2005